Cycloguanil

Error creating thumbnail:

Cycloguanil synthesis

Cycloguanil is a dihydrofolate reductase inhibitor used as an antimalarial drug. It is a metabolite of proguanil, functioning by inhibiting the dihydrofolate reductase of Plasmodium species, thereby blocking the synthesis of tetrahydrofolate. Tetrahydrofolate is essential for the synthesis of purines and pyrimidines, which are necessary for DNA synthesis. Therefore, cycloguanil effectively hampers the replication of the malaria parasite.

Mechanism of Action

Cycloguanil works by selectively inhibiting the enzyme dihydrofolate reductase (DHFR) in Plasmodium species, the parasites responsible for malaria. DHFR is crucial for the parasitic cell's ability to synthesize DNA, as it is involved in the production of tetrahydrofolate, a form of folate that acts as a carrier of carbon groups in the synthesis of purines and pyrimidines. By inhibiting DHFR, cycloguanil deprives the parasite of the necessary components for DNA synthesis, leading to its death.

Clinical Use

Cycloguanil is not commonly used as a standalone treatment for malaria but is a metabolite of proguanil. Proguanil, often in combination with atovaquone (as in the combination drug Malarone), is used for the prevention and treatment of malaria. The combination exploits the synergistic effects of both drugs, with atovaquone disrupting mitochondrial electron transport in the parasite and cycloguanil inhibiting DHFR.

Resistance

Resistance to cycloguanil has emerged in various strains of Plasmodium falciparum, the most deadly of the malaria parasites. This resistance is primarily due to mutations in the gene encoding for DHFR, which reduce the drug's affinity for the enzyme without significantly affecting the enzyme's ability to catalyze the reduction of dihydrofolate to tetrahydrofolate. The spread of resistance has limited the effectiveness of cycloguanil in some regions, making it necessary to use other antimalarial strategies or drug combinations.

Pharmacokinetics

As a metabolite of proguanil, the pharmacokinetics of cycloguanil are closely related to those of its parent compound. Proguanil is metabolized in the liver to cycloguanil through the action of cytochrome P450 enzymes. The pharmacokinetics of cycloguanil can be affected by factors that influence proguanil metabolism, including genetic polymorphisms in cytochrome P450 enzymes and interactions with other drugs that are metabolized by the same pathway.

Side Effects

The side effects of cycloguanil are generally mild and are often related to its parent compound, proguanil. Common side effects include gastrointestinal disturbances, such as nausea and vomiting, and headaches. As with any antimalarial drug, the risk of side effects must be balanced against the risk of developing malaria, particularly in regions where the disease is endemic.